Goldman Sachs
EWTX icon

Goldman Sachs’s Edgewise Therapeutics EWTX Stock Holding History

Goldman Sachs’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-69,800
Closed -$1.73M – 6642
2025
Q4 		$1.73M Buy
+69,800
New +$1.4M ﹤0.01% 4719

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs's EWTX Position: Q1 2026 in Review

Goldman Sachs reduced its Edgewise Therapeutics (EWTX) stake by 12% in Q1 2026, selling an estimated $2.55M and leaving 629,820 shares worth $19.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2441.

Goldman Sachs first reported a position in EWTX in Q1 2021 and has held it in 19 quarters since. The position peaked at $31.9M in Q1 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Goldman Sachs held 629,820 shares of Edgewise Therapeutics worth $19.8M as of Q1 2026.
  • Goldman Sachs sold 88,552 Edgewise Therapeutics shares in Q1 2026, an estimated $2.55M.
  • Edgewise Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2441 holding.
  • Goldman Sachs first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Edgewise Therapeutics position peaked at $31.9M in Q1 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.